DR. JOHN PETER SEIBYL, M.D.
Neurology at Temple St, New Haven, CT
License number
Connecticut 029212
Category
Neurology
Type
Diagnostic Neuroimaging
Address
Address
2
60 Temple St SUITE 8B, New Haven, CT 06510
14 Wilford Ave, Branford, CT 06405
14 Wilford Ave, Branford, CT 06405
Phone
(203) 401-4300
(203) 488-7982
(203) 488-7982
Personal information
See more information about JOHN PETER SEIBYL at radaris.comName
Address
Phone
14 Wilford Ave, Branford, CT 06405
Branford, CT
14 Wilford Ave, Branford, CT 06405
Professional information
See more information about JOHN PETER SEIBYL at trustoria.com
Dr. John P Seibyl, New Haven CT - MD (Doctor of Medicine)
Dr. John P Seibyl, New Haven CT - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Psychiatry), Nuclear Medicine
Address:
THE INSTITUTE FOR NEURODEGENERATIVE DISORDERS
60 Temple St SUITE 8B, New Haven 06510
(203) 401-4300 (Phone), (203) 401-4304 (Fax)
60 Temple St SUITE 8B, New Haven 06510
(203) 401-4300 (Phone), (203) 401-4304 (Fax)
Certifications:
Nuclear Medicine, 1994, Psychiatry, 1992
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Case Western Reserve University School of Medicine
Graduated: 1986
Greenwich Hosp Assocs
Yale University School Of Medicine
Case Western Reserve University School of Medicine
Graduated: 1986
Greenwich Hosp Assocs
Yale University School Of Medicine
Method Of Determining The Activity Of A Central Nervous System Drug On Striatal Dopamine Transporter Populations
Method Of Determining The Activity Of A Central Nervous System Drug On Striatal Dopamine Transporter Populations
US Patent:
2003013, Jul 10, 2003
Filed:
Dec 31, 2002
Appl. No.:
10/334239
Inventors:
Peter Snyder - West Hartford CT, US
Robert Innis - Rockville MD, US
John Seibyl - Branford CT, US
Akira Kugaya - New Haven CT, US
Stephen Williams - Stonington CT, US
Robert Innis - Rockville MD, US
John Seibyl - Branford CT, US
Akira Kugaya - New Haven CT, US
Stephen Williams - Stonington CT, US
Assignee:
Pfizer Inc.
International Classification:
A61K051/00, A61K031/405
US Classification:
514/419000, 424/001110
Abstract:
This invention relates to a method of predicting the activity of a CNS drug on striatal dopamine transporter populations. The method uses SPECT brain imaging to predict the activity of antidepressants or anxiolytic agents on striatal dopamine transporter populations. The method uses the increase in dopamine transporter populations as a marker for predicting sexual dysfunction side effects, as well as to determine proper dosing for antidepressants or anxiolytics agents in order to avoid the sexual dysfunction side effects.
Dopamine And Noradrenergic Reuptake Inhibitors In Treatment Of Schizophrenia
Dopamine And Noradrenergic Reuptake Inhibitors In Treatment Of Schizophrenia
US Patent:
5447948, Sep 5, 1995
Filed:
May 7, 1992
Appl. No.:
7/880127
Inventors:
John P. Seibyl - Branford CT
John H. Krystal - New Haven CT
Dennis S. Charney - Hamden CT
John H. Krystal - New Haven CT
Dennis S. Charney - Hamden CT
Assignee:
Yale University - New Haven CT
International Classification:
A61K 31415, A61K 31445
US Classification:
514393
Abstract:
Mazindol and other dopamine and/or noradrenergic reuptake inhibitors are effective to treat negative symptoms in schizophrenia.